title: Epicutaneous immunization with protein antigen TNP-Ig alleviates TNBS-induced colitis in mice.
abstract: BACKGROUND
  Ulcerative colitis (UC) is a chronic inflammatory autoimmune disease with limited treatment modalities. The animal model of colitis induced by treatment with trinitrobenzene sulfonic acid (TNBS-colitis) is commonly used to test new therapies of this disease. In our previous work we found that epicutaneous (EC) immunization with protein antigen induced a state of profound immunosuppression that inhibited inflammatory response in contact sensitivity, in experimental autoimmune encephalomyelitis (EAE) and in allogeneic skin graft rejection.
  
  
  METHODS
  TNBS-induced colitis was used as an experimental model.
  
  
  RESULTS
  In our current work, we showed that EC immunization with TNP-conjugated mouse immunoglobulin (TNP-Ig) prior to induction of TNBS-colitis alleviates disease severity what was determined by the body weight, the length and the weight of the colon, the histological activity index (HAI) and myeloperoxidase activity (MPO). Observed amelioration of the disease in TNP-Ig patched mice was accompanied with decreased production of IFN-γ and IL-17A by splenocytes. Additionally, spleen cells isolated from mice EC immunized with TNP-Ig prior to colitis induction showed increased production of IL-10 suggesting that this cytokine might be involved in inhibiting inflammatory response in the colon.
  
  
  CONCLUSIONS
  This work shows that EC immunization with protein antigen prior to TNBS-colitis induction ameliorates disease and observed suppression of inflammatory response in the colon might be mediated by IL-10.
authors: Department of Medical Biology, Jagiellonian University College of Medicine, Kopernika 7, PL 31-034 Kraków, Poland.
authors: Monika
authors: M
authors: Majewska-Szczepanik
authors: Marta
authors: M
authors: Góralska
authors: Katarzyna
authors: K
authors: Marcińska
authors: Magdalena
authors: M
authors: Zemelka-Wiącek
authors: Anna
authors: A
authors: Strzępa
authors: Iwona
authors: I
authors: Dorożyńska
authors: Marian
authors: M
authors: Szczepanik
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D003106:Colon / Q000201:enzymology / Q000276:immunology* / Q000473:pathology; D003888:Desensitization, Immunologic / Q000379:methods*; D004195:Disease Models, Animal; D005260:Female; D007136:Immunoglobulins / Q000008:administration & dosage*; D018836:Inflammation Mediators / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D020381:Interleukin-17 / Q000378:metabolism; D051379:Mice; D009504:Neutrophils / Q000201:enzymology / Q000276:immunology; D009195:Peroxidase / Q000378:metabolism; D012720:Severity of Illness Index; D012867:Skin / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D013997:Time Factors; D057968:Transdermal Patch; D014301:Trinitrobenzenes / Q000008:administration & dosage*; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D015415:Biomarkers; C556062:IL10 protein, mouse; C098680:Il17a protein, mouse; D007136:Immunoglobulins; D018836:Inflammation Mediators; D020381:Interleukin-17; D014301:Trinitrobenzenes; D016753:Interleukin-10; D007371:Interferon-gamma; D014302:Trinitrobenzenesulfonic Acid; D009195:Peroxidase